A Phase I/II Study Evaluating The Dosing, Safety, Efficacy, And Biological Activity Of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Neoadjuvant Chemotherapy (NACT) In Patients Actively Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer